vs
Side-by-side financial comparison of Commercial Bancgroup, Inc. (CBK) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
Commercial Bancgroup, Inc. is the larger business by last-quarter revenue ($23.1M vs $18.6M, roughly 1.2× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 41.3%, a 24.4% gap on every dollar of revenue.
Commercial Bancgroup, Inc.CBKEarnings & Financial Report
Commercial Bancgroup, Inc. operates as a U.S. regional bank holding company that provides a full suite of retail and commercial banking products and services to individual consumers, small and medium-sized businesses, and local institutional clients. Its core offerings include deposit accounts, lending solutions, wealth management, and tailored financial advisory services for regional markets.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
CBK vs SCYX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.1M | $18.6M |
| Net Profit | $9.5M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | — | 56.3% |
| Net Margin | 41.3% | 65.7% |
| Revenue YoY | — | 1808.5% |
| Net Profit YoY | 9.7% | 376.5% |
| EPS (diluted) | $0.69 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $23.1M | — | ||
| Q4 25 | $23.5M | $18.6M | ||
| Q3 25 | $22.8M | $334.0K | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $257.0K | ||
| Q4 24 | — | $977.0K | ||
| Q3 24 | — | $660.0K | ||
| Q2 24 | — | $736.0K |
| Q1 26 | $9.5M | — | ||
| Q4 25 | $9.9M | $12.3M | ||
| Q3 25 | $9.5M | $-8.6M | ||
| Q2 25 | — | $-6.9M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-2.8M | ||
| Q2 24 | — | $-14.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 56.3% | ||
| Q3 25 | 53.8% | -2516.5% | ||
| Q2 25 | — | -701.0% | ||
| Q1 25 | — | -3350.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1563.6% | ||
| Q2 24 | — | -1255.0% |
| Q1 26 | 41.3% | — | ||
| Q4 25 | 42.2% | 65.7% | ||
| Q3 25 | 41.4% | -2572.2% | ||
| Q2 25 | — | -504.8% | ||
| Q1 25 | — | -2097.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -425.5% | ||
| Q2 24 | — | -1964.4% |
| Q1 26 | $0.69 | — | ||
| Q4 25 | $0.72 | $0.25 | ||
| Q3 25 | $0.77 | $-0.17 | ||
| Q2 25 | — | $-0.14 | ||
| Q1 25 | — | $-0.11 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | — | $-0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $40.0M |
| Total DebtLower is stronger | $118.2M | — |
| Stockholders' EquityBook value | — | $49.4M |
| Total Assets | $2.3B | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $40.0M | ||
| Q3 25 | $154.8M | $37.9M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $68.8M | ||
| Q2 24 | — | $73.0M |
| Q1 26 | $118.2M | — | ||
| Q4 25 | $166.8M | — | ||
| Q3 25 | $100.1M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $49.4M | ||
| Q3 25 | $245.2M | $36.4M | ||
| Q2 25 | — | $44.5M | ||
| Q1 25 | — | $50.5M | ||
| Q4 24 | — | $55.1M | ||
| Q3 24 | — | $58.5M | ||
| Q2 24 | — | $60.4M |
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | $59.0M | ||
| Q3 25 | $2.2B | $51.1M | ||
| Q2 25 | — | $60.7M | ||
| Q1 25 | — | $67.9M | ||
| Q4 24 | — | $90.6M | ||
| Q3 24 | — | $99.0M | ||
| Q2 24 | — | $107.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $18.4M | ||
| Q3 25 | $28.0M | $-8.7M | ||
| Q2 25 | — | $-7.5M | ||
| Q1 25 | — | $-7.5M | ||
| Q4 24 | — | $-24.0M | ||
| Q3 24 | — | $765.0K | ||
| Q2 24 | — | $-10.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $26.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 115.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 6.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.50× | ||
| Q3 25 | 2.96× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBK
| Net Interest Income | $20.5M | 89% |
| Noninterest Income | $2.6M | 11% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
